Xlife Sciences AG

  • ISIN: CH0461929603
  • Land: Schweiz

Nachricht vom 23.12.2020 | 09:48

Xlife Sciences AG: Exit of a project company

Xlife Sciences AG / Key word(s): Investment
Xlife Sciences AG: Exit of a project company

23-Dec-2020 / 09:48 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Xlife Sciences AG: Exit of a project company

More than 20 million euros transaction completed

Xlife Sciences AG has successfully realized its 60% stake of the project company Araxa Biosciences GmbH in Veraxa Biotech AG (formerly Velaxa AG). This transaction has a total value of more than 20 million euros and Xlife Sciences AG will now become a part of the Board of Directors of Veraxa as a minority shareholder. Veraxa Biotech AG is positioned as a leading provider in the identification and development of functional antibodies and drug conjugates.

Xlife Sciences AG will exceed its earnings expectations for 2020 with this first completed transaction since founding of the company. Araxa Biosciences GmbH was a spin-off from the European Molecular Biology Laboratory EMBL in Heidelberg and was founded by Xlife Sciences AG in summer 2019. Over the past one and a half years, Xlife has invested nearly one million euros in the company. In collaboration with various industry experts, the technological development of Araxa has been successfully advanced.

About Veraxa Biotech AG
Veraxa Biotech AG identifies and develops functional antibodies and antibody drug conjugates (ADC's) for the bio- and pharmaceutical industry in exchange for license agreements. The aim is to accelerate the safe development of medical drugs, as well as to enhance the probabilities of drug developments in various clinical phases. Using this technology, Veraxa Biotech AG can screen millions of b-cells in one single step in less than 48 hours for functional antibodies and additionally also modify them with drug conjugates.

About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch

For media inquiries:
Oliver R. Baumann, CEO Xlife Sciences AG, Tel. +41 44 385 84 60, oliver.baumann@xlifesciences.com

23-Dec-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“


11 Perlen im „GBC Fonds Champions 2021“

Im Rahmen der aktuellen Studie „GBC Fonds Champions 2021“ haben wir elf versteckte Fondsperlen mit dem Kriterium einer Mindestbewertung von 4 von 5 GBC-Falken ausgewählt. Auch tragen wir dem gesteigerten Investoreninteresse nach nachhaltigen Investments Rechnung und haben drei nachhaltige Fonds ausgewählt. Übrigens, die Fonds aus unserer letzten Ausgabe haben im Schnitt eine Performance von plus 31,8 % erreicht.

News im Fokus

Bayerische Motoren Werke Aktiengesellschaft: Wesentliche vorläufige Ergebniskennzahlen der BMW AG für das erste Quartal 2021 über Markterwartungen

19. April 2021, 18:52

Aktueller Webcast

Nordex SE

Conference Call 11.05.2021 (Webcast)

11. Mai 2021

Aktuelle Research-Studie


Original-Research: CO.DON AG (von Sphene Capital GmbH): Buy

19. April 2021